{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.2555","pValueComment":"The p value is two-sided from the log rank test stratified by the randomization stratification factors of IPSS classification and FAB classification","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.60","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"Cox proportional hazards model stratified on the randomization factors of FAB and IPSS with model term of treatment.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.2562","paramType":"Hazard Ratio (HR)","paramValue":"0.83","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.9","upperLimit":"25.5","value":"20.66"},{"groupId":"OG001","lowerLimit":"12.4","upperLimit":"22.5","value":"15.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"The time to transformation to AML was defined as the number of days from the date of randomization until the date of documented AML transformation, defined as a bone marrow blast count ≥ 30% independent of baseline bone marrow count. Patients who did not transform to AML were censored at the date of last follow-up or date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"OG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"OG001","title":"Conventional Care"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population. Participants who were transformed to AML are 78 for azacitidine and 71 for conventional care. Remaining participants were censored based on the last bone marrow assessment.","reportingStatus":"POSTED","timeFrame":"Day 1 (randomization) to 42 months","title":"Kaplan-Meier Estimates for Median Time to Transformation to Acute Myeloid Leukemia (AML)","type":"SECONDARY","unitOfMeasure":"months"}